This is a preview of subscription content, log in via an institution to check access.
References
Nishimoto N, Yoshizaki K, Miyasaka N, et al.: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50:1761–1769.
Nishimoto N, Hashimoto J, Miyasaka N, et al.: Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor (SAMURAI): — Evidence of clinical and radiographic benefit from an X-Ray Reader-Blinded Randomized Controlled Trial of Tocilizumab. Ann Rheum Dis 2007, Epub ahead of print.
Resnan-Targoff B: Medical therapy—Where are we now? Am J Health Syst Pharm 2006, 63(Suppl):511–518.
van der Helm-van Mil AH, le Cessie S, van Dongen H, et al.: A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007, 56:433–440.
Rights and permissions
About this article
Cite this article
Crawford, M., Moreland, L. Clinical trials report. Curr Rheumatol Rep 9, 393–395 (2007). https://doi.org/10.1007/s11926-007-0062-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11926-007-0062-6